dc.creator | Villadiego Luque, Francisco Javier | es |
dc.creator | García-Arriaza, Juan | es |
dc.creator | Ramírez Lorca, Reposo | es |
dc.creator | García Swinburn, Roberto | es |
dc.creator | Cabello Rivera, Daniel | es |
dc.creator | Rosales Nieves, Alicia E. | es |
dc.creator | Muñoz Cabello, Ana María | es |
dc.creator | López Barneo, José | es |
dc.creator | Toledo Aral, Juan José | es |
dc.date.accessioned | 2024-01-08T12:58:23Z | |
dc.date.available | 2024-01-08T12:58:23Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Villadiego Luque, F.J., García-Arriaza, J., Ramírez Lorca, R., García Swinburn, R., Cabello Rivera, D., Rosales Nieves, A.E.,...,Toledo Aral, J.J. (2023). Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate. Nature neuroscience, 26 (2), 226-238. https://doi.org/10.1038/s41593-022-01242-y. | |
dc.identifier.issn | 1097-6256 | es |
dc.identifier.uri | https://hdl.handle.net/11441/153027 | |
dc.description.abstract | Vaccines against SARS-CoV-2 have been shown to be safe and effective but their protective efficacy against infection in the brain is yet unclear. Here, in the susceptible transgenic K18-hACE2 mouse model of severe coronavirus disease 2019 (COVID-19), we report a spatiotemporal description of SARS-CoV-2 infection and replication through the brain. SARS-CoV-2 brain replication occurs primarily in neurons, leading to neuronal loss, signs of glial activation and vascular damage in mice infected with SARS-CoV-2. One or two doses of a modified vaccinia virus Ankara (MVA) vector expressing the SARS-CoV-2 spike (S) protein (MVA-CoV2-S) conferred full protection against SARS-CoV-2 cerebral infection, preventing virus replication in all areas of the brain and its associated damage. This protection was maintained even after SARS-CoV-2 reinfection. These findings further support the use of MVA-CoV2-S as a promising vaccine candidate against SARS-CoV-2/COVID-19. | es |
dc.format | application/pdf | es |
dc.format.extent | 54 | es |
dc.language.iso | eng | es |
dc.publisher | Nature Publishing Group | es |
dc.relation.ispartof | Nature neuroscience, 26 (2), 226-238. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/acceptedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Fisiología Médica y Biofísica | es |
dc.relation.projectID | PID2019-105995RB-I00 | es |
dc.relation.projectID | PID2020-114481RB-I00 | es |
dc.relation.projectID | RTI2018-096629-B-I00 | es |
dc.relation.projectID | PID2019-106410RB-I00 | es |
dc.relation.projectID | RD16/0011/0025 | es |
dc.relation.projectID | US-1380891 | es |
dc.relation.projectID | PECOVID-0078-2020 | es |
dc.relation.projectID | PY20_ 01312 | es |
dc.relation.projectID | COV20/00151 | es |
dc.relation.projectID | 202120E079 | es |
dc.relation.projectID | 2020E84 | es |
dc.relation.projectID | CF01-00008 | es |
dc.relation.projectID | PRJ201502629 | es |
dc.relation.projectID | AEI/10.13039/501100011033 | es |
dc.relation.projectID | SEV-2013-0347 | es |
dc.relation.projectID | SEV-2017-0712 | es |
dc.identifier.doi | 10.1038/s41593-022-01242-y | es |
dc.contributor.group | Universidad de Sevilla. CTS-516: Fisiología Celular y Biofísica | es |
dc.journaltitle | Nature neuroscience | es |
dc.publication.volumen | 26 | es |
dc.publication.issue | 2 | es |
dc.publication.initialPage | 226 | es |
dc.publication.endPage | 238 | es |
dc.contributor.funder | Spanish Ministry of Science and Innovation/Spanish Research Agency | es |
dc.contributor.funder | Red TerCel ISCIII | es |
dc.contributor.funder | Consejeria de Economia, Conocimiento, Empresas y Universidad | es |
dc.contributor.funder | Junta de Andalucia | es |
dc.contributor.funder | Fondo COVID-19 grant (Spanish Health Ministry, Instituto de Salud Carlos III) | es |
dc.contributor.funder | CSIC | es |
dc.contributor.funder | La CaixaImpulse grant | es |
dc.contributor.funder | European Commission-NextGenerationEU, through the CSIC's Global Health Platform (PTI Salud Global) | es |
dc.contributor.funder | European Research Council (ERC) Spanish Government | es |
dc.contributor.funder | Spanish Government | es |